insights_auto
Why is UNC up 4.01%?
Dive Deeperchevron_right
UNC:ETR
UCB SA
€218.00
arrow_upward
+4.01%(+8.40) 1D
Oct 20, 5:30:00 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UNC...
Open
€206.70
High
€218.00
Low
€206.70
Mkt. cap
41.65B
Avg. vol.
264.00
Volume
215.00
Dividend
0.47%
Quarterly dividend
€0.25
Ex-dividend date
May 4, 2026
P/E ratio
19.28
52-wk high
€287.20
52-wk low
€197.90
EPS
€11.31
No. of employees
9K
Open
€206.70
High
€218.00
Low
€206.70
Mkt. cap
41.65B
Avg. vol.
264.00
Volume
215.00
Dividend
0.47%
Quarterly dividend
€0.25
Ex-dividend date
May 4, 2026
P/E ratio
19.28
52-wk high
€287.20
52-wk low
€197.90
EPS
€11.31
No. of employees
9K
News stories
From web sources and news partners
ad-hoc-news.de
·
4 hours ago
UCB stock: Barclays keeps Hold rating and EUR 260.00 target for UCB stock
ad-hoc-news.de
·
9 hours ago
UCB reports FDA approval for Zilbrysq device: UCB stock gains 2.05 percent
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9K
FoundedJan 18, 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com